New drugs in myeloproliferative disorders

Srdan Verstovsek, Ruben Mesa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The classic BCR-ABL-negative myeloproliferative disorders (MPDs) include polycythemia vera (PV), essential thrombocythemia (ET), and agnogenic myeloid metaplasia. Included in this latter group are also postthrombocythemic and postpolycythemic myeloid metaplasia (1). This last group has been the subject of focus and nomenclature changes by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF) is designated for de novo presentations, and the myelofibrosis (MF) that develops in the setting of either ET or PV is referred to as post-ET MF or post-PV MF, respectively.

Original languageEnglish (US)
Title of host publicationMyeloproliferative Disorders
Subtitle of host publicationBiology and Management
PublisherCRC Press
Pages143-160
Number of pages18
ISBN (Electronic)9781420061635
ISBN (Print)9781420061628
StatePublished - Jan 1 2007
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Verstovsek, S., & Mesa, R. (2007). New drugs in myeloproliferative disorders. In Myeloproliferative Disorders: Biology and Management (pp. 143-160). CRC Press.